US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...
Citadel takes $384.5 million short position in GSK - FT
Citadel, the hedge fund owned by billionaire Ken Griffin, has taken a short position in GlaxoSmithKline (NYSE:GSK), a British ...
Hedge fund Citadel takes short position in GSK, FT reports
Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...
GSK shares shorted by leading U.S. hedge fund, The Times reports
The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s ...
PharmiWeb5d
Pharmaceutical Market: Shaping the Future of Healthcare and Medicine
Pharmaceutical Market Size and Growth 2025 to 2034The global pharmaceutical market size was valued at USD 1,607.07 billion in ...
Effervescent Tablet Market to Grow by USD 4.80 Billion (2024-2028), Boosted by Aging Population Adoption & AI's Impact on Market Trends - Technavio
Report on how AI is redefining market landscape - The global effervescent tablet market size is estimated to grow by USD 4.80 ...
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...
GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views — Update
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion-pound ...
Analgesics Market Expected To Reach USD 131.29 Billion by 2032,Growing at CAGR of 4.6% | Johnson & Johnson, Pfizer Inc., GlaxoSmithKline
Exploring Analgesics as a Key Painkiller Types & Their Role in Pain ReliefUnited States, New York, Feb. 04, 2025 (GLOBE ...
Business Today13d
Budget 2025: Pfizer, Novartis, AstraZeneca to benefit from BCD exemptions; pharma stocks mixed
AstraZeneca Pharma India Ltd and GSK Pharmaceuticals Ltd shall be the beneficiaries of the budget announcements the Finance Minister Nirmala Sitharaman, wherein she announced to fully exempt as ...